Literature DB >> 10590024

Clinical and molecular spectrum of somatic mosaicism in androgen insensitivity syndrome.

P M Holterhus1, J Wiebel, G H Sinnecker, H T Brüggenwirth, W G Sippell, A O Brinkmann, K Kruse, O Hiort.   

Abstract

We recently found that postzygotic de novo mutations occur at the expected high rate of an X-linked recessive mutation in androgen insensitivity syndrome. The resulting somatic mosaicism can be an important molecular determinant of in vivo androgen action caused by expression of the wild-type androgen receptor (AR). However, the clinical relevance of this previously underestimated genetic condition in androgen insensitivity syndrome has not been investigated in detail as yet. Here, we present the clinical and molecular spectrum of somatic mosaicism considering all five patients with mosaic androgen insensitivity syndrome, whom we have identified since 1993: Patient 1 (predominantly female, clitoromegaly), 172 TTA(Leu)/TGA(Stop); patient 2 (ambiguous), 596 GCC(Ala)/ACC(Thr); patient 3 (ambiguous), 733 CAG(Gln)/ CAT(His); patient 4 (completely female), 774 CGC(Arg)/TGC (Cys); and patient 5 (ambiguous), 866 GTG(Val)/ATG(Met). Serum sex hormone binding globulin response to stanozolol, usually correlating well with in vivo AR function, was inconclusive for assessment of the phenotypes in all tested mosaic individuals. An unexpectedly strong virilization occurred in patients 1, 3, and 5 compared with phenotypes as published with corresponding inherited mutations and compared with the markedly impaired transactivation caused by the mutant ARs in cotransfection experiments. Only the prepubertal virilization of patients 2 and 4 matched appropriately with transactivation studies (patient 4) or the literature (patients 2 and 4). However, partial pubertal virilization in patient 4 caused by increasing serum androgens and subsequent activation of the wild-type AR could not be excluded. We conclude that somatic mosaicism is of particular clinical relevance in androgen insensitivity syndrome. The possibility of functionally relevant expression of the wild-type AR needs to be considered in all mosaic individuals, and treatment should be adjusted accordingly.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10590024     DOI: 10.1203/00006450-199912000-00009

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  6 in total

1.  Disorders of sex development: diagnostic approaches and management options-an islamic perspective.

Authors:  Nasir Am Al Jurayyan
Journal:  Malays J Med Sci       Date:  2011-07

2.  Structural basis of androgen receptor binding to selective androgen response elements.

Authors:  Paul L Shaffer; Arif Jivan; D Eric Dollins; Frank Claessens; Daniel T Gewirth
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-22       Impact factor: 11.205

3.  Predicting puberty in partial androgen insensitivity syndrome: Use of clinical and functional androgen receptor indices.

Authors:  Ngee Lek; Rieko Tadokoro-Cuccaro; Jonathan B Whitchurch; Bismoy Mazumder; Harriet Miles; Philippa Prentice; Trevor Bunch; Karolina Zielińska; Veronika Metzler; Nigel P Mongan; David M Heery; Ieuan A Hughes
Journal:  EBioMedicine       Date:  2018-10-11       Impact factor: 8.143

4.  Phenotypic and biochemical characteristics and molecular basis in 36 Chinese patients with androgen receptor variants.

Authors:  Hui Zhu; Haijun Yao; Yue Xu; Yan Chen; Bing Han; Nan Wang; Hao Wang; Qiang Zhang; Wenjiao Zhu; Yuanping Shi; Hua Sun; Shuangxia Zhao; Huaidong Song; Yang Liu; Jie Qiao
Journal:  Orphanet J Rare Dis       Date:  2021-03-09       Impact factor: 4.123

5.  Identification of an AR Mutation-Negative Class of Androgen Insensitivity by Determining Endogenous AR Activity.

Authors:  N C Hornig; M Ukat; H U Schweikert; O Hiort; R Werner; S L S Drop; M Cools; I A Hughes; L Audi; S F Ahmed; J Demiri; P Rodens; L Worch; G Wehner; A E Kulle; D Dunstheimer; E Müller-Roßberg; T Reinehr; A T Hadidi; A K Eckstein; C van der Horst; C Seif; R Siebert; O Ammerpohl; P-M Holterhus
Journal:  J Clin Endocrinol Metab       Date:  2016-09-01       Impact factor: 5.958

6.  Next generation sequencing (NGS) to improve the diagnosis and management of patients with disorders of sex development (DSD).

Authors:  L A Hughes; K McKay-Bounford; E A Webb; P Dasani; S Clokie; H Chandran; L McCarthy; Z Mohamed; J M W Kirk; N P Krone; S Allen; T R P Cole
Journal:  Endocr Connect       Date:  2019-02       Impact factor: 3.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.